DBV Technologies: DBV Technologies Announces Filing of 2015 "Document de Référence" and 2015 Annual Report on Form 20-F

Press Release
Montrouge, France, April 28, 2016

DBV Technologies Announces Filing of 2015 "Document de Référence" and 2015 Annual Report on Form 20-F

                                                                                                                                                                      

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced the filing of its 2015 Annual Report "Document de Référence" for the year ended December 31, 2015 with the French market authority "Autorité des Marchés Financiers" (AMF) and the filing of its Annual Report on Form 20-F for the year ended December 31, 2015 with the U.S. Securities and Exchange Commission (SEC).

These documents can be accessed on the Investor Relations section of the Company's website at www.dbv-technologies.com (http://www.dbv-technologies.com/). In addition, the "Document de Référence" is available on the AMF's website at www.amf-france.org (http://www.amf-france.org/) and the Form 20-F is available on the SEC's website at www.sec.gov (http://www.sec.gov/). Printed copies of the "Document de Référence" are available at the Company's headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France. Any shareholder can request a printed copy of the Form 20-F, free of charge, upon request. Requests should be directed to DBV Technologies, Attn: Investor Relations, 177-181 avenue Pierre Brossolette 92120 Montrouge, France.

About DBV Technologies 

DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, New York. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website at www.dbv-technologies.com (http://www.dbv-technologies.com/).

DBV Technologies Contact
Susanna Mesa Senior Vice President, Strategy [phone] [e-mail] (mailto:[e-mail])
Media Contacts
Erinn White, Centron PR [phone] [e-mail] (mailto:[e-mail])   Marion Janic, Rooney & Associates [phone] [e-mail]
Media Contacts, Europe Caroline Carmagnol, Alize RP - Relation Presse [phone] [e-mail] (mailto:[e-mail])

20F (http://hugin.info/156437/R/2008215/742700.pdf)

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

HUG#2008215